VBL Therapeutics raises $40 million in revived Nasdaq IPO

– After the fiasco of the failed IPO in August, the drug development company scaled down the offering. VBL Therapeutics has raised $40 million at a company value of $120 million in a revived IPO on Nasdaq. More...

3 Israeli biomed cos fall sharply after Nasdaq IPOs

– BioBlast’s share lost 38% of its value, Macrocure 25%, and VBL Therapeutics 18%. –   The shares of three Israeli biomedical companies that completed their IPOs last Wednesday More...

VBL Therapeutics prices Nasdaq IPO

– The clinical stage biotech company is selling 5.4 million ordinary shares at $12 each. Clinical-stage biotech company VBL Therapeutics has announced the pricing of its Nasdaq IPO. The company is selling More...

Good News From Israel No. 12 : Business, Science, Technology And More

– In the 22nd Dec 2013 edition of Israel’s good news:   ECONOMY & BUSINESS Inflation falls by 0.4 per cent.  An 8.1% drop in the prices of fresh vegetables means that Israel’s annual inflation More...